Boston Scientific (BSX) enters into a USD 2bln accelerated share repurchase agreement; expects net impact of USD 0.02 to adj. EPS in FY26; will have USD 3bln remaining under share repurchase authorisation after the ASR

Boston Scientific's announcement of a $2 billion accelerated share repurchase agreement is likely to boost investor confidence, as it signals strong cash flow and commitment to returning capital to shareholders. The anticipated impact of $0.02 to adjusted EPS in FY26 is modest but reinforces a positive outlook on profitability, particularly with $3 billion left under their repurchase authorization. Investors should watch for potential upward price support and increased interest among healthcare equities, given the broader context of capital returns in the sector.